Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeglea Biothera (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,187
  • Shares Outstanding, K 16,810
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -27,240 K
  • 36-Month Beta -0.16
  • Price/Sales 25.51
  • Price/Cash Flow N/A
  • Price/Book 2.61

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.50 +6.67%
on 04/19/18
10.83 -26.13%
on 03/26/18
-2.37 (-22.85%)
since 03/23/18
3-Month
5.12 +56.25%
on 02/09/18
11.35 -29.52%
on 03/20/18
+1.35 (+20.30%)
since 01/25/18
52-Week
2.81 +184.70%
on 08/17/17
11.35 -29.52%
on 03/20/18
+1.10 (+15.94%)
since 04/25/17

Most Recent Stories

More News
Aeglea BioTherapeutics Prices Public Offering of Common Stock

Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea Initiates Lung Cancer Combination Study With Keytruda

Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

AGLE : 7.89 (-4.71%)
AZN : 35.17 (+0.14%)
MRK : 59.24 (-1.41%)
ABBV : 91.00 (-0.39%)
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA(R) (Pembrolizumab) Combination Trials

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics Appoints Dr. Ivana MagovčeviÄ?-Liebisch to Board of Directors

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results

Repeat Doses of Company's Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels

AGLE : 7.89 (-4.71%)
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today...

AGLE : 7.89 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

2nd Resistance Point 9.13
1st Resistance Point 8.71
Last Price 7.89
1st Support Level 7.88
2nd Support Level 7.47

See More

52-Week High 11.35
Fibonacci 61.8% 8.09
Last Price 7.89
Fibonacci 50% 7.08
Fibonacci 38.2% 6.07
52-Week Low 2.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar